DESTINY Breast 03 from #ESMO21 presenter Dr. Erika Hamilton

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancerПодробнее

#ESMO21 Expert Video Report on targeting in HER2-positive metastatic breast and lung cancersПодробнее

#ESMO21 Expert Video Report on HER2-positive metastatic breast cancerПодробнее

Highlights from ESMO: DESTINY-Breast03Подробнее

Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast CancerПодробнее

Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika HamiltonПодробнее

Dr. Erika Hamilton Presents Safety Update DESTINY breast03Подробнее

Dr. Erika P. Hamilton on ONT-380 in HER2-Positive Breast Cancer Patients With Brain MetastasesПодробнее

Dr. Erika P. Hamilton on Difficulties of Treating Brain Metastases in Breast CancerПодробнее

Dr. Erika Hamilton Discusses monarchE at ESMO20 for OncoAlertПодробнее

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03Подробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее

HER2 Positive Breast Cancer Algorithm - OncBrothers (Rohit & Rahul Gosain) w/ Dr. Erika HamiltonПодробнее

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1Подробнее

Dr. Erika Hamilton on Scripps NewsПодробнее

Dr. Erika P. Hamilton on The Shifting Treatment Paradigm in HER2-Positive Breast CancerПодробнее

Dr. Erika Hamilton on Late Stage Breast Cancer on LX News - NBCLXПодробнее

Dr. Erika Hamilton Shares an Important Breast Cancer Research Update - NewsyПодробнее